Drug Trial Radar · NCT07549412
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,020
Planned (sponsor's estimate)
Start
May 6, 2026
Primary completion
Oct 16, 2029
Study completion Oct 16, 2029
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluridine/tipiracil (FTD-TPI) plus bevacizumab.
Conditions
- Metastatic Colorectal Cancer
Interventions
Precemtabart tocentecanDrug
Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle.
BevacizumabDrug
Bevacizumab, administered intravenously every 3 weeks on Day 1 of each 21-day cycle or every 2 weeks on Day 1 and Day 15 of each 28-day cycle.
Trifluridine/Tipiracil (FTD-TPI)Drug
FTD-TPI, tablet, administered orally twice daily, on Days 1 to 5 and Days 8 to 12 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm 1, 2 and 3: Overall SurvivalTime frame: Time from date of randomization to death, assessed approximately up to average of 19 months
Locations
116 sites in 19 countries. Site status is shown where the registry gives one.
UCSF Mount Zion Medical Ctr
San Francisco, California · Recruiting
Rocky Mountain Cancer Centers, LLP- Aurora
Lone Tree, Colorado · Recruiting
Florida Cancer Specialists-Broadway
Fort Myers, Florida · Recruiting
Florida Cancer Specialists - St. Petersburg Bayfront
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists East - FCS EAST - West Palm Beach
West Palm Beach, Florida · Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
Illinois CancerCare PC
Peoria, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Profound Research LLC at Cancer and Leukemia Center
Sterling Heights, Michigan · Recruiting
Minnesota Oncology Hematology, P.A.
Saint Louis Park, Minnesota · Recruiting
Missouri Cancer Associates - 150518964
Columbia, Missouri · Recruiting
White Plains Hospital Medical and Wellness PRIME
White Plains, New York · Recruiting
Prisma Health Cancer Institute, ITOR, CRU
Greenville, South Carolina · Recruiting
Avera Cancer Institute - 300127370
Sioux Falls, South Dakota · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology, P.A. - Abilene - 300210366
Abilene, Texas · Recruiting
Texas Oncology-South Austin
Austin, Texas · Recruiting
Texas Oncology DFW
Bedford, Texas · Recruiting
Texas Oncology- San Antonio
San Antonio, Texas · Recruiting
Texas Oncology, P.A. - Tyler
Tyler, Texas · Recruiting
Virginia Oncology Associates
Newport News, Virginia · Recruiting
Blue Ridge Cancer Care - 300202915
Roanoke, Virginia · Recruiting
Investigaciones Clinicas Moleculares ICM
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Centro Oncologico de Excelencia
San Juan, Argentina · Recruiting
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, Argentina · Recruiting
Instituto de Oncologia de Rosario
Rosario, Santa Fe Province, Argentina · Recruiting
GenesisCare North Shore (Oncology)
St Leonards, New South Wales, Australia · Recruiting
Icon Cancer Centre Chermside
Chermside, Queensland, Australia · Recruiting
Mater Misericordiae Ltd - PARENT
South Brisbane, Queensland, Australia · Recruiting
Flinders Medical Centre
Bedford Park, South Australia, Australia · Recruiting
LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie
Salzburg, Austria · Recruiting
AKH - Medizinische Universität Wien - Klinik für Innere Medizin 1
Vienna, Austria · Recruiting
Cliniques Universitaires Saint-Luc - STL
Brussels, Belgium · Recruiting
Grand Hospital de Charleroi - PARENT
Charleroi, Belgium · Recruiting
UZA - Account 3
Edegem, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
BC Cancer - Vancouver - BC Cancer Agency
Vancouver, British Columbia, Canada · Recruiting
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada · Recruiting
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.